Sleep, rem - Open Access .click

Results 81 to 90 of about 36,381 (240)

A Holistic Wellness Prescription for Parkinson's Disease: Evidence‐Based Perspectives and Unmet Needs

Movement Disorders Clinical Practice, EarlyView.
Abstract Background In modern medicine the concept of wellness is often accompanied by various misconceptions arising from several factors, including a lack of clear definitions, the commercialization of wellness, and prevailing biases and stereotypes.
Indu Subramanian +40 more
wiley +1 more source

Evaluating the Role of α‐Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties

Movement Disorders Clinical Practice, EarlyView.
Abstract Background α‐synuclein seeding amplification assay (α‐synuclein SAA) development as a diagnostic biomarker for Parkinson's disease (PD) has shown promising results over the past decade. However, the utility of these assays in the prediction of disease progression is unclear.
Daniel Belete +5 more
wiley +1 more source

The Effect of Baclofen on Alterations in the Sleep Patterns Induced by Different Stressors in Rats

Journal of Pharmacological Sciences, 2009
We have previously reported that sleep patterns are significantly affected by both physical and psychological stress induced by a communication box ; however, the mechanism by which stress alters sleep patterns was not established.
Ranji Cui +3 more
doaj +1 more source

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes +6 more
wiley +1 more source

LRRK2 as a Potential Disease‐Modifying Target in Sporadic Parkinson's Disease

Movement Disorders, EarlyView.
Abstract A growing understanding of the role that leucine‐rich repeat kinase 2 (LRRK2) plays in Parkinson's disease (PD) supports continued focus on this enzyme as a therapeutic target for PD. Accumulating evidence suggests that there are phenotypic, neuropathologic, and biological similarities between sporadic PD (sPD) and familial forms in which ...
Anthony E. Lang +12 more
wiley +1 more source

REM sleep and neurodegeneration

Journal of Sleep Research
SummarySeveral brainstem, subcortical and cortical areas are involved in the generation of rapid eye movement (REM) sleep. The alteration of these structures as a result of a neurodegenerative process may therefore lead to REM sleep anomalies.
Laura Pérez‐Carbonell, Alex Iranzo
openaire +3 more sources

Constipation Is Linked to Neuroinflammation in Early Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Constipation is a risk factor for the onset and accelerated progression of Parkinson's disease (PD), but the mechanisms underlying this association are unknown. Neuroinflammation in PD has been demonstrated in postmortem and neuroimaging studies; however, its relationship with constipation has not been investigated.
Marta Camacho +8 more
wiley +1 more source

Accelerating Medicines Partnership® Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research

Movement Disorders, EarlyView.
Abstract Background Recent advances in proteomic profiling have enabled its use as a powerful approach in elucidating molecular mechanisms underlying Parkinson's disease, enabling the identification of disease‐associated protein alterations and candidate biomarkers for diagnosis, progression, and therapeutic response.
Victoria J. Dardov +21 more
wiley +1 more source

Discordance of Dopaminergic Dysfunction and Subcortical Atrophy by α‐Synuclein Status in Sporadic and Genetic Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Parkinson's disease (PD) is characterized by predominantly neuronal α‐synuclein pathology and dopaminergic dysfunction. Cerebrospinal fluid (CSF) seeding amplification assays (SAA) detect α‐synuclein aggregates in vivo, but not all patients with PD have a positive SAA.
Michael Tran Duong +186 more
wiley +1 more source

Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha‐Synuclein Seed Amplification Assay

Movement Disorders, EarlyView.
Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker +30 more
wiley +1 more source

rem sleep
medicine
sleep

depression
pharmacology
rem

polysomnography
paradoxical sleep
therapeutics